|
Post-progression survival of patients with metastatic hormone-sensitive prostate cancer (mHSPC) who received darolutamide or placebo: Post hoc analysis of ARASENS. |
| |
|
Honoraria - AstraZeneca; Bristol-Myers Squibb; EUSA Pharma; Ipsen; Janssen Cilag; Merck Serono; MSD; Pfizer |
Consulting or Advisory Role - AstraZeneca; Bayer/Vital; Bristol-Myers Squibb; Eisai; EUSA Pharma; Gilead Sciences; Ipsen; Janssen Cilag; Merck Serono; MSD; Novartis; Pfizer; Takeda |
Research Funding - Bayer/Vital (Inst); Bristol-Myers Squibb (Inst); Intuitive Surgical (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen Cilag; Merck Serono; MSD |
| |
|
Consulting or Advisory Role - Ambrx; Amgen; Astellas Pharma; Bayer; Janssen Oncology; Lilly; Novartis; Pfizer |
Research Funding - Bayer (Inst); ESSA (Inst); Janssen Oncology (Inst); Lilly (Inst); ORIC Pharmaceuticals (Inst) |
| |
|
Honoraria - Academic CME; AstraZeneca; AstraZeneca; Bayer; Bayer; Clinical Care Options; Great Debates and Updates; Medscape; Merck; Novartis; Research to Practice; Targeted Oncology |
Consulting or Advisory Role - AstraZeneca; Bayer; Bayer; Convergent Therapeutics; GlaxoSmithKline; GlaxoSmithKline; Janssen; Merck; Novartis; Novartis; Pfizer; Tango Therapeutics; Tempus |
Research Funding - Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Genentech (Inst); PCCTC (Inst); Pfizer (Inst) |
Patents, Royalties, Other Intellectual Property - TITLE: Dual Inhibition of MET and VEGF for the treatment of castration resistant prostate cancer and osteoblastic bone metastases. Applicant/Proprietor Exelexis, Inc. Application No/Patent No. 11764665.4- 1464 Application No/Pat; TITLE: METHOD OF TREATING CANCER Docket No: Serial Number: 224990/10-016P2/311733 61/481/671 Application Filed on: 5/2/2011; TITLE: SYSTEMS AND METHODS FOR TISSUE IMAGING, 3676 Our File: Serial Number: UM-14437/US-1/PRO 60/923,385 UM-14437/US-2/ORD 12/101,753 |
Travel, Accommodations, Expenses - Bayer |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst) |
Consulting or Advisory Role - Amgen (Inst); Arvinas; Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); CureVac; Daiichi Sankyo Europe GmbH (Inst); Janssen Oncology (Inst); Macrogenics; MSD (Inst); Novartis (Inst); Orion; Pfizer (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Janssen; MSD; Pfizer |
| |
|
|
| |
|
|
Stock and Other Ownership Interests - Bayer |
| |
|
|
| |
|
|
| |
|
Honoraria - AAA/Endocyte/Novartis; Amgen; Astellas Pharma; AstraZeneca; Bayer; Ferring; Janssen; MSD Oncology; Myovant Sciences; Pfizer; Sanofi |
Consulting or Advisory Role - Astellas Pharma; Bayer; Ferring; Janssen; Myovant Sciences; Pfizer/Astellas; Sanofi; Steba Biotech; Takeda |
Speakers' Bureau - Amgen; Astellas Pharma; Astellas Pharma; Janssen |
Research Funding - Ferring (Inst) |
Expert Testimony - Steba Biotech |
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Bayer; Ferring; Janssen; Sanofi |